ema reviews benefits, risks of flupirtine
TRANSCRIPT
Reactions 1447 - 13 Apr 2013
■ The EMA’s Pharmacovigilance Risk AssessmentCommittee (PRAC) will review the benefits and risks offlupirtine-containing medicines, following a requestfrom Germany. The German medicines agency(BfArM) has received an increasing number of reportsof liver disorders associated with use of the analgesic,ranging from reports of elevated liver enzymesthrough to liver failure. In total, the German ADRdatabase contains 330 reports of such liver disorders,including 15 which had a fatal outcome or resulted inliver transplantation. The German agency has alsonoted a lack of data supporting the drug’seffectiveness in treating long-term pain. In 2011, thetotal patient exposure to flupirtine in Germany wasestimated to be 28.1 million defined daily doses.EMA. Review of flupirtine-containing medicines started. Internet Document :[2 pages], 7 Mar 2013. Available from: URL: http://www.ema.europa.eu 803085789
1
Reactions 13 Apr 2013 No. 14470114-9954/10/1447-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved